EL.En. S.p.A. (ELN) Earnings Call Transcript & Summary

September 11, 2026

Borsa Italiana IT Health Care Health Care Equipment and Supplies earnings 80 min

Earnings Call Speaker Segments

Nicola Fiore

unknown
#1

Thanks for joining El.En.'s call, where we'll be presenting the financial results for the first half of 2026. This session is being recorded, and at the close of the presentation you'll have a chance to ask questions. Joining us today are Andrea Cangioli, El.En.'s Chief Executive Officer, and Enrico Romagnoli, who serves as El.En.'s Chief Financial Officer and Investor Relations Manager. Before we get started, I'd like to point out that management will be making certain statements on this conference call about future expectations, plans, and prospects. Such statements are forward-looking and carry risks and uncertainties that might cause actual results to differ materially from what is expressed or implied. Certain statements in this call — including those addressing the company's beliefs, plans, objectives, estimates, or expectations of possible future results or events — constitute forward-looking statements. Forward-looking statements involve known or unknown risks, including general economic and business conditions in the industry in which we operate. Should our assumptions prove inaccurate, these statements may be affected. As a result, no forward-looking statement can be guaranteed, and actual future results, performance, or achievements may differ materially from those expressed or implied by such forward-looking statements. The company assumes no obligation to update the contents or the forward-looking statements to reflect events or circumstances that may arise after the date hereof.

Nicola Fiore

unknown
#2

Once the presentation wraps up, anyone with a question should lift their virtual hand. Whoever asked first gets to speak first, in the order requests come in. Thanks for being with us today. We're starting the conference call now, and I'll hand things over to Andrea Cangioli. Andrea, the floor is yours.

Andrea Cangioli

executive
#3

Thank you. Thanks, Nicola. Thanks, Bianca. Good afternoon, everyone, and I appreciate you being on this call. Enrico Romagnoli will host the call alongside me, as he usually does. I'll attempt to keep the financial figures to a minimum and instead stick to describing what has happened over these six months, leaving the financial portion to Enrico. There are a number of interesting topics for us to discuss in this first half of 2026. On one hand, the outstanding results from our existing activities, and on the other, the announced divestiture of the laser cutting division. The first half confirmed how strong the group's growth trajectory is and the direction we have been following for some time now — a growing focus on the medical sector. After last year's sale of Penta Laser Zhejiang, we went a step further, finalizing at the start of August an agreement to sell the majority stake in Cutlite Penta and the remaining parts of our laser cutting business to the market leader, TRUMPF. To frame this deal properly, Cutlite heads the laser cutting division of the El.En. Group, which includes a few distribution companies, among them the long-term owned Cutlite do Brasil, and in 2025 accounted for €121 million and change in revenues and €2 million in EBIT, basically breakeven in terms of net income, also because of interest expense on a net financial debt of about €16 million.

Andrea Cangioli

executive
#4

During 2025 and the opening half of 2026, the company has in some way been grappling with a complicated market backdrop. One thing I'd highlight is the uncertainty and volatility that hit our core market — Italy's domestic one — because of tax-policy announcements backing capex that were never followed through on time with actual implementation. Above all, Cutlite, the group, has now spent over 2 years operating while an M&A deal has been looming. Initially, when the plan was to sell it alongside our Chinese operations, and on the strength of that news alone, it came close to losing its US business, and more recently, when chatter about a possible sale to TRUMPF was used by rivals to erode the confidence of customers and prospective customers in Cutlite. With Cutlite joining the TRUMPF world, we are confident we are handing Cutlite and its over 200 employees the finest chance to strengthen their distinctive capabilities inside an organization entirely concentrated on the same business area, one that will build the right setting and synergies for Cutlite to keep growing with the success it deserves. The transaction as such hands over the business on terms that factor in its low profitability and substantial indebtedness.

Andrea Cangioli

executive
#5

So the price will be set based on future performance as well, which means the price we can foresee right now equates to a certain loss on the P&L when you factor in the asset's carrying value. But looking purely at the financial side, the impact on our net financial position is already strongly positive, since we're paying down the financial debt. What matters more for where we're headed is how the sale strategically repositions our business scope — the medical sector's share of our revenues climbs from 72% in 2025 to 92% in the first half of 2026 on the new perimeter. That said, on laser cutting, let me finish the picture for the industrial sector before I turn to medical. With the laser cutting divestment done, what's left of our industrial activities is now built around three pillars: marking, laser sources, and the conservation of artistic heritage. Marking is handled by Lasit, which specializes in systems for identification and decoration of typically small surfaces, and by solid-state laser sources. Small logos, barcodes, QR codes are what a Lasit marking system typically produces, while the outlet markets span a range running from automotive to the promotional and fashion world, from medical devices to electronic consumer goods.

Andrea Cangioli

executive
#6

Ot-Las handles large-surface systems used for decoration as well as for certain technical applications. Through its industrial division, El.En. supplies mid-power CO2 laser sources and advanced scanning systems both to Ot-Las and to outside parties, and it also develops and engineers special-purpose systems that combine our laser sources with our scanning expertise. Preserving artistic heritage is, far and away, the most thrilling and fulfilling activity — not because of financial reward, but because of the beauty of the masterpieces that our technologies bring back to life. Commercially it keeps growing, yet it remains and will remain very small. Taken together, these operations will add roughly €40 million to consolidated revenues for the full year 2026. On the sales side, margins in this business are closer to — and at times even above — those seen in the medical field. The same may hold for EBIT and EBIT margin once certain volume thresholds are reached; those thresholds were not achieved this year, though they were achieved previously, including recently, by Lasit, the biggest entity in this organization, which generates revenues of just under €30 million annually. Let's now turn to our core business. In the medical sector, results were robust and spread widely across our operating units: DEKA, Quanta System, Asclepion, ASA, and our application segments.

Andrea Cangioli

executive
#7

Every one of them added positively. The aesthetic segment was a standout, posting double-digit growth, driven in particular by anti-aging applications — an area where we hold an international leadership position thanks to our micro-ablative CO2 technologies and other innovative noninvasive platforms such as Onda PRO and Red Touch PRO, plus a range of pico- and nanosecond short-pulse systems that see extensive use for the toning application, especially across the Far East areas. That growth in the aesthetic segment carries particular meaning given the headwinds we face in the hair removal segment — a trend that has now been underway for several years and that in this 2026 has continued, also because of uncertainties the wars are imposing on the Middle East area, which ranks among the most important markets for us. Believe me, we are not leaving any stone unturned to relaunch this segment, which still accounts for roughly one-third of our aesthetic system sales. Just to give you an example, months ago we had planned to take part in the Dubai Derma exhibit this week, exhibition, investing both in the exhibition booth and in the traveling of our staff and our selected KOLs. The booth had to stay with our distributor only in a barely visited venue, and our staff could not fly to the area.

Andrea Cangioli

executive
#8

Also, this isn't in my notes, but I want to share with you that Onda's success right now—which is certainly among the biggest growth drivers over the last year—is so strong that, for the first time ever, we're seeing a large number of competitors attempting to blatantly copy our device. Certain Far East manufacturers in particular have put substantial effort into trying to replicate Onda, and they're trying to distribute systems that imitate Onda without even coming close on performance, while of course creating a great deal of confusion in the market. I just received a report—that's why I'm bringing this up—listing 19 copies of Onda PRO currently available on the market. Naturally, we are combating this trend through the appropriate legal channels, but nothing like this has ever happened before for any product in our range. Returning to the point that in aesthetics we grew double-digit despite the decline in hair removal sales, I should add that the good news here is that even with hair removal's weaker performance, we are doing very well. Moreover, overall margins in the segment are improving, since the revenue decline involved the most competitive application segment, while our flagship innovative anti-aging systems carry higher margins because their value proposition is well received in the market, as I just mentioned.

Andrea Cangioli

executive
#9

Surgical applications likewise delivered a robust performance, with support coming from urology as well as from the CO2 laser solution, for both ENT and gynecology. Within the surgical segment, the biggest sales volume by far was achieved by urology system sales, and future consumables sales are driven by the ongoing expansion of the installed base. Every surgical procedure carried out with a urology laser system calls for a sterile optical fiber, and that consumable is supplied by us to our customer base. So, alongside system sales, fiber sales are tracking a growth trend quite well, and this is materially accretive to our profitability, since the sales and marketing operation expense tied to selling a sterile fiber is far lower than the expense and effort required to sell a laser system. During the first half of 2026, we launched a significant activity in the urology field. When the distribution agreement with its long-standing distributor in the United States expired, Quanta System proceeded to set up its own distribution and logistics hub in the United States, which began operating in the second quarter. The favorable effects of the subsidiary's operation on our business and our P&L have been evident from the very start, as Quanta USA delivers additional sales volume, gross margin, and EBIT, while consolidating Quanta System's leadership within the El.En.

Andrea Cangioli

executive
#10

On both sales volume and profitability, the group performed well. The therapy segment also made a positive contribution, though its growth was more modest. In July we signed a very significant agreement with our US distributor, which brings closer cooperation between ASA—the company responsible for the therapy business—and its longtime distributor, which is by far its largest customer. ASA, together with El.En., provided the distributor with funding through a convertible loan; that loan is expected to convert initially into 20% of the distributor's shares, and it also triggers an option allowing us to raise our equity stake further down the road. For the group this transaction is small, but for the ASA business and the therapy business it is very relevant. During the six months we also went through a very important organizational change: our General Manager, Paolo Salvadeo, resigned for personal reasons, and his employment ended this month of July. I want to thank him for the valuable contribution he made to our activities and for the excellent job he did in improving the managerial performance of several individuals who worked closely with him. Building on these new capabilities, we were able to design a new organizational structure, particularly in the DEKA business unit, where Paolo worked here at our premises in Florence, and where certain managers stepped up to greater responsibility, reporting directly to the executive directors without any need to replace the general manager position.

Andrea Cangioli

executive
#11

Our view of the markets is still favorable. This isn't news to any of you. We have strong confidence in what we can do and in the organization we've built to go after the growth that our end markets appear capable of supporting. We're in a period of strong profitability right now, and that isn't coming at the cost of investment — including investment through the P&L, particularly in R&D. I look at the products behind our present success, such as Onda PRO. I know how they were conceived, engineered, produced, and made successful in the market. I know we have what it takes to launch new products that, whether built on new technologies or on enhancements to how well existing technologies work, will be able down the road to match the success of our flagship devices. I'll hand things over to Enrico to discuss our financial results.

Enrico Romagnoli

executive
#12

Thank you, Andrea. Good afternoon, everyone. As always, I'll give a brief comment on the first-half financial results that were released yesterday. The half-yearly report was prepared in line with the IFRS accounting standard, reclassifying the contribution of Cutlite Penta's industrial cutting division into discontinued assets, liabilities, and income statement results under IFRS 5 for the current year. For the prior year, though, the reclassification applied only to the income statement, because of the binding agreement signed and announced on August 7, which covers the sale of 80% of the laser cutting business division. In the first half of 2026, the group closed with revenues above €246 million, an increase of more than 9% versus the same period in 2025, €226 million?, confirming the positive performance seen in the first quarter. During the first half, the medical segment grew over 10%, driven by a strong second quarter, plus 11.4% against 9.2% in the Q1. Revenue in the remaining industrial sector, by contrast, declined. Gross margin for the first half came in at €122.8 million, up 12.4% from the €109.2 million on June 2025. The better sales margin booked in the quarter reflects a more favorable business mix, helped by the growing weight of the medical sector, which, after the sales of the laser cutting business, now accounts for over 92% of the revenue.

Enrico Romagnoli

executive
#13

Operating expense came in at €26.9 million, essentially flat versus €26.5 million in 2025, and its effect on revenue fell from 11.8% to 10.9%, which points to a positive operating leverage effect. Staff costs were €47.1 million, a rise of 4.4% from €45.1 million in 2025, while their impact on revenue dropped from 20% to 19.1%. The notional cost tied to employees' stock option plans was €0.5 million for the period, versus €1 million in 2025. EBITDA reached €48.7 million, an increase of over 30% from €37.5 million? in the first half of 2025. The EBITDA margin went from 16.6% in 2025 to 19.8% in 2026. Depreciation, amortization, and provision declined from €5.9 million in 2025 to €5.3 million in June 2026, and that movement reflects the net effect of greater depreciation and risk provisions combined with a lower provision for credit risk. EBIT was €43.4 million, a substantial gain versus €31.6 million in the first half of 2025, and the EBIT margin climbed from 14% to 17.6%. As part of presenting the consolidated income statement under IFRS 5, owing to a purely accounting technique, EBIT carries a penalty of roughly €1.4 million; excluding that, the half-yearly result would have come to approximately €45 million.

Enrico Romagnoli

executive
#14

The effect of that cost on the income statement gets offset by revenue of an equal amount booked in the discontinued operation line, so the accounting treatment leaves the net result unchanged. Financial income came to €1.7 million, versus a loss of €2 million in the same period a year earlier. That improvement came mainly from the net foreign exchange result, which went from a loss of €3.4 million in June 2025 to a gain of €0.3 million this period. The remaining amount came from returns on the group's cash holdings, which are invested in short- and mid-term financial instruments. The share of profit and loss of associated company was driven mainly by the combined effect of the group's stakes in Elesta, a positive result of €93,000, and the loss share reported by Penta Laser Zhejiang in China, €0.6 million, and Withus Japan, a €0.3 million loss. The majority interest in these two companies was disposed of during 2025; even so, they kept reporting a negative result in 2026 as well. The negative balance of other net income and expenses stemmed from the full impairment of the investment in Epic International, Inc.

Enrico Romagnoli

executive
#15

Owned by the parent company El.En. Pretax income came in at a positive €43.4 million, which is a substantial rise from the €29.3 million recorded on June 2025. The result from the discontinued operation stems mainly from the contribution made by the cutting division Cutlite Penta, in line with IFRS 5. To be specific, it takes in the net loss posted by that business unit plus an extraordinary loss of €3.9 million, which comes from impairing the carrying amount of the discontinued operation on the basis of the price that is to be received under the agreement currently in place. Then, on the positive side, this item also includes the purely different accounting classification tied to applying IFRS 5, which calls for the economic effects of the sale to be summarized, whatever their nature, in one single line of the income statement — result from discontinued operation — placed right before the period result. That positive amount offset the negative amount I mentioned earlier when we are discussing EBIT. Group net result reached €26.1 million, against €17.9 million? in the first half, which is a 45.4% increase. The tax rate for the period stands at 32%. On this chart, you can see the pro forma income statement excluding IFRS 5, with the cutting division — discontinued in the earlier version — consolidated in.

Enrico Romagnoli

executive
#16

If IFRS 5 hadn't been applied, first-half 2026 revenue would have come in at €300 million, versus €285 million in the first half of 2025 — a rise of 5.2%. Under that income statement setup, the industrial sector's result would have looked weaker: minus 8% instead of minus 4%, with the cutting segment to blame. On gross margin, the same drivers we flagged under the earlier version of the income statement were still at work — above all the larger share of medical revenue in total turnover and a better sales mix inside the medical segment. Even with the cutting segment included, EBITDA and EBIT posted robust double-digit gains of 23.6% and 29.7%, respectively, along with margin improvement as a impact on sales. Turning to the balance sheet, comparisons with the start of the year are shaped by the fact that the cutting business unit was reclassified as a discontinued operation only as of June 30, 2026. Invested capital came down slightly. The net working capital-to-sales ratio matches last year's figure, whereas ROCE improved markedly. Investments over the first six months totaled €7.5 million. Now to cash flow and net financial position: the group's net financial position rose by roughly €12 million in the first half, going from €172.2 million at December 2025 to €184.5 million at June 2026.

Enrico Romagnoli

executive
#17

The chart shows that net working capital typically rises during the first half of the year as part of the group's business cycle, and it absorbed roughly €15 million in cash. Capital expenditure, which we mentioned earlier, came to €7.5 million?, and dividends paid in May by the parent company and some subsidiaries totaled €21.3 million. The contribution to the net financial position from the asset held for sale reflects the derecognition of €16 million in net financial debt as of December 2025 tied to the discontinued business. Revenue rose across every medical application segment. The aesthetic segment turned in a strong performance, up 11%, driven by the anti-aging system despite weakness in hair removal. Surgical activities posted the strongest results, up 15%, mainly on growth of the system for urology. The therapy segment also did well, up 1%. Slower revenue growth in after-sales service and consumable sales reflects the loss of revenue from Withus last year, €1.5 million, net of which growth would have been 6.2%. Within that segment, nearly 60% of revenues come from sterile optical fibers for urological surgical procedures, which saw a 12.1% revenue increase over the half year. In the industrial application sector, revenues for the period were significantly below the prior year, mainly because of the disposal of the laser cutting business, which reduced the scope of operations.

Enrico Romagnoli

executive
#18

Regarding the industrial application sector, the discontinued cutting division is no longer reflected on the chart. Results for the residual division were negative, at minus 17%, and laser sources came in at minus 15%, whereas after-sales service and components revenue was especially strong, posting a turnover of €5.7 million in the first half 2026, up 34% from the €4.3 million in the same period a year earlier. These activities also contributed 30% of the residual overall industrial turnover, confirming the growing weight of the most recurring and visible revenue components. To give a fuller picture of the business trend, it should be noted that turnover for the first half of 2026 attributable to the laser cutting sector equaled €53.8 million, down from the €60.2 million recorded in the first half of 2025, minus 10.6%. By geography, the medical sector declined 16% in Italy compared with robust growth in Europe, plus 8%, and particularly strong performance in non-European markets, plus 17%, which represented the main growth area in consolidated revenue during the period. In Europe, Asclepion's extensive network supported an encouraging result in the DACH region, while non-European market growth was driven primarily by the Far East.

Enrico Romagnoli

executive
#19

Italy’s industrial segment posted a solid rebound, up 8% on the strength of Lasit, while in Europe it saw a drop of 15%. In non-European markets, conditions held steady. Andrea, over to you for the guidance.

Andrea Cangioli

executive
#20

Alright. So as you can see, we basically confirmed the guidance. Revenue will increase by more than 5%, and we will achieve a better EBIT margin than the prior year. That probably warrants a bit more explanation. At the board level, we discussed the message that comes across from this confirmed guidance — it apparently looks disappointing, since you would expect that once the weakest business unit is no longer part of financial reporting, better financial results would follow and, as a result, a stronger guidance would be issued. Let me explain why that isn't the situation and why our guidance points you toward very strong financial results. The guidance we issued in March was, and still is, defined in terms of improvement measured against the previous year. A portion of the sales and profitability recovery we anticipated for 2026 was supposed to come from a strong rebound in the cutting business, which performed rather poorly in 2025 and was loss-making during the second half. So under the new scope, the benchmark becomes far more demanding, particularly given the outstanding results of the medical business in the second half of 2025. By confirming the guidance figures against a different benchmark, we are in effect confirming that the second-half results will be extremely strong.

Andrea Cangioli

executive
#21

With that, our prepared remarks are done, and we're ready to take your questions.

Bianca Fersini-Mastelloni

unknown
#22

We’re ready to begin the Q&A portion now. Kindly lift your virtual hand if you’d like to ask something. Giovanni Selvetti of Berenberg has the first question. Please proceed, Giovanni.

Giovanni Selvetti

analyst
#23

Hi folks, is my audio coming through okay?

Enrico Romagnoli

executive
#24

Correct.

Bianca Fersini-Mastelloni

unknown
#25

Yes.

Giovanni Selvetti

analyst
#26

Hi there, and congratulations on the results. I’ve got a few questions. First, what’s behind the softness in the medical sector in Italy, and do you anticipate any improvement in H2? Second, maybe just to remind us: with the new optical fiber capacity expansion in Samarate with Quanta, what’s the maximum revenue that can be generated in this field? In your H1 report, you also mentioned greater efficiencies and automation at this new plant — I was wondering whether it’s reasonable to assume that optical fibers run at an EBIT margin higher than the 20% of overall medical sales. Third, maybe about Quanta: if you could elaborate a bit more on what you mentioned earlier — that you’re already starting to see positive results. I was wondering whether you’ll also use Quanta distribution sales for Asclepion in surgical, which based on your financial report already has some new FDA approved devices. The last one is more strategic, in the sense that you’ve been doing an excellent job, let’s say, disposing of assets recently. I was wondering if, given also the cash position, which increased further and is going to increase further in H2, you also have some targets for buying something, or if you just prefer to invest in organic growth?

Giovanni Selvetti

analyst
#27

Thanks.

Andrea Cangioli

executive
#28

Thanks, Giovanni. Let me take the questions in the order they came. On the medical sector in Italy — yes, revenues did decline. We're fairly confident that professional aesthetics accounts for the bulk of that drop. Last year we also had some one-time sales, and they were quite substantial one-time sales. We saw a burst of sales driven by a very unusual lead, let's put it that way. We know we're recovering in that segment — in professional beauty — and we already did so in July and August, nearly closing the gap. We also know that in medical, where we sell through DEKA's network, the Renaissance brand — which covers both DEKA and Quanta — has a very strong backlog, and I can't say whether we'll manage to fully catch up, but we will certainly be able to narrow that gap considerably in the second half of the year. As for fiber optics sales, the sterile ones, they rose by more than 10% in the half — in the first half. That's a trend that ought to hold, and it won't depend on any gain in production capacity, since we still have sufficient capacity for the next one year.

Andrea Cangioli

executive
#29

The investment in the new fiber-optic manufacturing facility is well defined. We began with the real estate, after that we added the white room, and then we brought in the automation, which is already installed, but achieving the full certification to supply this medical device will take more time, and full certification for the plant to be operational isn't anticipated until the second half of next year. In the interim, we expect, particularly given the ongoing sales of system and therefore the expansion of the installed base, that this growth trend in fiber sales will persist, as I mentioned, with no need for added capacity since we can reach that point using existing capacities, though the new capacity will be ready to come in one year from now, when volumes will be materially higher than today, if all goes according to plan. The new distribution in the United States for Quanta is one of the investments on the internal growth path, also to establish a connection to your fourth question, Giovanni. This company is a hub that manages more than direct sales — it manages other distributors as well — and this is work that the former distributor was doing.

Andrea Cangioli

executive
#30

They contributed roughly €6 million in sales during the quarter—and mind you, we're only talking about one quarter here, even though our remarks cover the six-month period—but the company only began operating at the start of the second quarter. This is going to be a major contributor to sales in the surgical business. On the subject of Asclepion sales, you're correct. Asclepion is securing FDA clearance for the new device, and that device has certain particular features that set it apart from what Quanta offers. No, at this time there are no plans for the Quanta distribution hub to also serve Asclepion's laser system. Under our business strategy, Asclepion and Quanta do, naturally, compete in the marketplace. The sole place where they share a distribution network is Italy, where DEKA Renaissance handles streamlining of Quanta System's products. That used to be the case in Germany as well, but Quanta System recently chose to pursue a different distribution channel, and unless something changes, they're also running it on their own. In principle, as you know, our brands compete in a mild way, yet they compete globally, and therefore they don't rely on the same distribution partners. Lastly, on M&A and cash—you're right, the net financial position is improving and will keep improving.

Andrea Cangioli

executive
#31

Nothing is different when it comes to any potential transformational M&A deal. Just like we've done lately, our focus is on smaller deals where we have greater confidence about extending, above all, our distribution reach. I can say that we're looking at fresh deals in Europe as well as in the Far East, both involving Quanta and involving other businesses. By our own standards, we're fairly active in chasing opportunities from this angle, yet not one of the opportunities currently before us should be big enough that it consumes a significant share of the cash we hold. That's my reply. From this standpoint there really is nothing novel compared with what we've consistently stated over the past several years regarding how the company views expansion. We're growing well organically, and we're doing everything necessary to keep that growth going. So far we haven't come across anything appealing enough to justify a large-scale investment. It isn't that we aren't searching for one, but as I've explained, we intend to proceed very carefully, since once you become substantially bigger, particular complications—a fair number of them—arise around running the group and around its standing in the market, and we want to be certain we don't bring those on ourselves by committing a great deal of our cash and generating difficulties for how our group is organized.

Andrea Cangioli

executive
#32

It's not as though we aren't giving it any thought whatsoever, but we're being quite careful about taking a really significant step.

Giovanni Selvetti

analyst
#33

That’s very clear. Thanks.

Bianca Fersini-Mastelloni

unknown
#34

Moving on, we have a question from Carlo Maritano at Intermonte. Carlo, please go ahead.

Carlo Maritano

analyst
#35

Good afternoon, everyone. I have just three questions on my end. First, regarding the medical business: you noted earlier that Italy was somewhat soft during the second quarter, whereas the rest of the world performed strongly. You brought up the Far East. Could you give us additional detail on which countries are doing the best? And can you update us on the Middle East — is the situation returning to normal following the first quarter, or is the current situation still creating some disruption? My second question concerns the marking business, which stayed fairly weak in the second quarter. Looking at your results, gross margin and EBIT appear to be essentially at the same level as last year. Could you shed some light on what is driving the higher profitability despite the lower sales? The last one is about duties. I don't recall exactly how duties work in your case, but in asking other companies, some are reporting reimbursement of certain duties. Do you have any news on that front? Thank you.

Andrea Cangioli

executive
#36

All right. Once more, going in order — Far East and Middle East. In the Far East we're very strong. Right now, Korea is undoubtedly our best-performing country, and that matters enormously, particularly in aesthetics, because the trend in aesthetic procedures is shifting at present, and that shift places Korea among the world's leading sources of aesthetic trends. To be able to sell a technology in a country that has plenty of technology developers — many of them busy copying our systems today — is a sign of great vitality and great strength. When we discuss the Middle East for aesthetics, the countries that typically matter most are Korea, Japan, and Thailand. We're also performing very well in Indonesia now, which is something new, though in terms of population it is by far the most relevant country — the most relevant country in terms of population. That's the Far East. Middle East — what's normal and what isn't, war, not war — I mentioned this earlier, and seeing the Dubai Derma exhibition taking place, with our distributor and all his people inside the booth, we're getting used to something that isn't a war, but is close to a war in that area.

Andrea Cangioli

executive
#37

The key point is that some countries in the region are doing quite well. There's a willingness to keep going. We anticipate a number of visitors for the DEKA Academy, an academy we run periodically here in Florence. They're arriving from Iraq. They're arriving from Saudi Arabia. On the whole, Middle East sales remain weaker than last year. They didn't fall to zero, but they're simply weaker versus last year. On the marking business, I'm not certain which figures you're looking at regarding profitability, but I can say that this year we had lower sales both at Lasit and at El.En., where Lasit is 100% marking, although it also has its service side, and El.En. covers both marking and laser sources, since it produces both the laser sources and the laser scanning heads. We had a larger sales volume at Ot-Las, the company that makes large-surface marking systems, and so Ot-Las recovered in profitability, while Lasit lost profitability. That's where things stand. Perhaps we can look together at where you've seen an improvement in the marking business's profitability. I think it should be more or less in the same situation overall, because although marking and although the high margin is improving, the volume wasn't sufficient to cover.

Andrea Cangioli

executive
#38

When I mentioned that they have high margins, comparable to the medical system, perhaps I was actually talking about gross margin rather than EBIT margin. That's the one I had in mind. Lasit's EBIT margin is comparable to the medical system, and its gross margin is even higher. The other companies do have high gross margin, but because of the missing leverage effect, they never achieved interesting EBIT margins in the past. I'm very well prepared on tariffs because I actually spoke with our distributor for the cutting laser systems — which is somehow in the past, but still, we worked with him, and he's an important customer for Cutlite. We weren't operating any company in the United States when the tariffs kicked in. Right now the only operational company we have in the United States is Quanta, Inc., which, as I say, starts operating in April 2026. The companies received reimbursement in the month of July and in the month of June for the tariffs they paid in the first round of tariffs, the one that the Supreme Court deemed unconstitutional, and by this way allowing the path for reimbursement of this tariffs. The other tariffs that have been levied on the companies based on different principles are currently being paid.

Andrea Cangioli

executive
#39

Regarding the portion of tariffs our US distributors paid, they haven't informed us whether they receive reimbursement. It's likely they'll attempt to keep that information from us, since they were asserting higher costs and wanted us to take part somehow, in the past, in this undue expense that suddenly appeared in the transaction between them and us. My expectation is that they have been reimbursed for the share of tariffs they paid during that period, but as of today I don't have evidence. In any case, it isn't us. We don't get any wire from the IRS, because we don't directly operate any activity in the US, and the tariffs were levied and paid by our distributors.

Carlo Maritano

analyst
#40

Thanks. One more question I have relates to rates that have been climbing over the past several months. I'm curious whether you're seeing any signs of a slowdown coming from your clients, particularly in the US, or whether demand is currently so strong that interest rates don't matter as much.

Andrea Cangioli

executive
#41

Right now, in the US, on the whole we're doing very well. There is a bit of, let's say, minor concern — though it isn't broad-based; it's specific to certain product lines. In the coming weeks we'll be sitting down with our distributors and will have a clearer picture on this. As of now, we haven't received any claim, any request, or any excuse stemming from orders not being placed or being postponed in connection with the rise in interest rates and the higher cost for customers that keeps them from purchasing our systems. At this point, there is no effect from that standpoint.

Carlo Maritano

analyst
#42

Thanks.

Bianca Fersini-Mastelloni

unknown
#43

Next up, we have a question from Andrea Bonfà at Banca Akros. Andrea, please go ahead.

Andrea Bonfà

analyst
#44

Is my voice coming through?

Bianca Fersini-Mastelloni

unknown
#45

Correct.

Andrea Cangioli

executive
#46

Yes.

Andrea Bonfà

analyst
#47

Hi there. Good afternoon, everyone, and well done on the results, Andrea and Enrico. Very quickly — a few of my questions have actually already been covered, by the way. I'd like a brief update from your end on when the metal-cutting business disposal is expected to close. Then some clarity on how medical services performed, because if you're saying the fibers continue to grow at a double-digit rate and, despite some perimeter effect, services is flat, maybe you could comment on that. We would love to have a pro forma EBIT for '25 if that's possible, or we can try to work it out ourselves. That's more or less what I'm asking for now, in case I'll add something at the end. Thank you.

Andrea Cangioli

executive
#48

All right. You'll receive the pro forma EBIT for '25 shortly. Enrico will get it ready with no trouble, I'm confident. No problem at all. Yes, service has performed extremely well in fibers for the urological business, while in the aesthetic field overall it has been weaker. It's essentially time and material, and there's a one-time effect from the deconsolidation of Withus. We had the Japanese company whose majority we sold in March 2025; it was still included in the 2025 financials for the first two months, and in fact they had significant contracts on the installed base. Their revenue came solely from service, so there's a deconsolidation impact worth, I believe, something like 3% — 3%. Excluding that effect, growth would have been 6.something. We think that with certain aesthetic devices there's also a decrease in consumption and in cost, because we're selling more devices that require less in the way of maintenance and ongoing expense, and fewer devices that demand more maintenance and ongoing expense. In particular, bear in mind that a high-power hair removal laser consumes a lot of service, since it requires replacement of laser lamps and the laser head — which is not just a consumable but also a substantial technical service that has to be carried out by qualified service technicians.

Andrea Cangioli

executive
#49

Since demand for these devices is shrinking somewhat relative to our sales of simpler systems, we're seeing softer demand from that angle as well. Broadly speaking, my expectation is that the total aggregate will grow roughly in line with the remainder of the business once we reach the rest of the year, by the time the year is over.

Andrea Bonfà

analyst
#50

Regarding when the deal will close—

Andrea Cangioli

executive
#51

On the timing of closing, Andrea — yes, there are certain conditions that have to be met. I actually held meetings today with a potential buyer. They expect to close very quickly. The contract includes a six-month long-stop, what's called a long-stop period. Honestly, as of today I'd say we're very confident we'll close before the end of the year. Whether that lands in October, November, or December within the end of the year is hard to say right now. It shouldn't come down to several months — just this stretch. I really believe we'll be closing as soon as possible. We'd like to close during the month of October if that could be possible. We have to see whether we obtain all the related permission and the small things that are missing so the deal can be finalized in the way and the form in which it is to be finalized.

Andrea Bonfà

analyst
#52

Thanks a lot.

Bianca Fersini-Mastelloni

unknown
#53

Valentin Paul-Jahan from Stifel also has a question for us. Please go ahead, Valentin.

Valentin Paul-Jahan

analyst
#54

Good afternoon, everyone. Can you hear me clearly?

Enrico Romagnoli

executive
#55

Yes.

Andrea Cangioli

executive
#56

Hello there, yes.

Valentin Paul-Jahan

analyst
#57

Perfect, and thank you for taking my questions. You covered many of the things I was going to ask, but I can probably follow up a little on the industrial segment. If you could, maybe give us more color on the marketing decline in the rest of Europe, and elaborate on what the marketing exposures are by end market, such as automotive manufacturer and things like that. That's for the first question. Second, could you please give more color on the current gross margin level of industrial now that cutting has been put as a for-sale business, and the potential indication of the potential normative margin following the disposal of cutting activities. The third one would be what are the synergies between the industrial activities still within the group—marketing, laser sources, and others—and the medical activities? Does it make sense to further streamline the portfolio around medical activities? Considering capital allocation, should we expect the company to use its M&A firepower for bolt-on M&A only in medical, or could you also seize opportunities in industrial markets? Thanks.

Andrea Cangioli

executive
#58

Let's begin with the final question this time around, since I think it's pertinent. There isn't much overlap between the medical and industrial businesses in terms of synergies, and what exists is mostly technical. The plant producing the low-power RF CO2 laser sources — the ones found in every CO2 laser across the group — sits here in Florence, and the technology involved is identical to what's used at the factory building low- and mid-power CO2 laser sources for industrial use. As a matter of fact, the two operations collaborate in certain ways. Whenever one business hits a production peak, we leverage the other business's facility, despite the facilities being physically separate. Both work with comparable technology, and indeed the R&D for the laser source is a single effort later applied to that same type of technology, though at two distinct power levels. That's one significant technological synergy. A second major technological synergy involves the scanning system capabilities, which sit within the industrial division — and the medical division is a customer of it. The scanning systems run by El.En. and by Ot-Las are built on galvanometers that we produce at our El.En. facilities, both in Florence and at our Castellammare di Stabia site.

Andrea Cangioli

executive
#59

The industrial team also builds every scanner for the thousands of laser systems that rely on a scanner in medical applications — that covers all the CO2 lasers, all the Red Touch lasers, and likewise the majority of high-power surgical holmium lasers made by Quanta System and by Asclepion, which employ the galvanometer produced at El.En. as a component required to switch among the four laser sources that constitute the laser itself. Naturally, these would be separable. There is nothing that any of them wouldn't come through intact were they to be divided, but at this moment we aren't actively pursuing the disposal of any of these facilities. The entity with the least strategic interaction with the remainder of the group is Lasit, since Lasit doesn't use El.En.'s CO2 laser sources, except really from time to time, and they possess their own technology. Technologically speaking, they are entirely independent. Lasit's marking business is strategically more independent than Ot-Las's marking business, which depends on and relies upon laser sources and scanners produced by El.En. We hold no acquisitive ambition in the marking business today. We are running it as a historical business.

Andrea Cangioli

executive
#60

That's something that in the past also made possible advances in technology for medical applications. Right now, we don't see any compelling reason to push ahead with any further divestment of any asset in the industrial business. Your first and second questions were somewhat connected, and you were looking for some color on the lower volume in the marking business. Revenue in the marking business has declined, particularly in Europe. Europe is where our facilities are located. Lasit has distribution facilities in France, Spain, Poland, the UK, and Germany. I think sales performance was weaker in these countries. There were also some large accounts, large sales, that had to be pushed from the second quarter to the third quarter. At present, we can say that the budgeted amounts probably will not be reached for the year, but we are confident that our market position is not put at risk by any other market event, aside from the fact that overall demand was weaker. You wanted to know what the end-user markets are. Generally speaking, it's manufacturing. It varies. Among our most important customers, we have manufacturers in the automotive sector — not the car manufacturers directly, but the manufacturers of components for cars.

Andrea Cangioli

executive
#61

Magneti Marelli was one of our key customers — just to cite a widely recognized name — along with Brembo. Both are highly significant component makers serving the automotive sector. We also supplied some of the most advanced marking systems for motor enthusiasts to Ferrari and Maserati as well. We operate in the automotive business, which naturally isn't performing especially well at this stage. We sell to electrical component manufacturers such as Schneider, Schneider too. Bosch is among the biggest customers buying from us on a continual basis, so that takes us into consumer electrical components. Beyond that, we also have a presence in medical devices. Incidentally, our German distribution company was established in the Tuttlingen area, and Tuttlingen is the region of Germany where the majority of surgical steel device components get produced. Broadly put, Lasit supplies marking to every kind of manufacturing activity. When we review Lasit's laser system sales each month, they span entirely different systems, all within manufacturing. We aren't reliant on any single market segment, so to speak. I don't recall what you said regarding margin and gross margin, Valentin. Would you mind repeating your question about that?

Valentin Paul-Jahan

analyst
#62

Could you share where gross margin currently stands for the industrial division? Yes, please go ahead.

Andrea Cangioli

executive
#63

That figure is above what we see in medical today. Normally, both Lasit and Ot-Las are able to sell at margins over 50%, and since that's what the market is calling for, only occasionally do we take a different approach to a sale, because we don't depend on distributors. When it comes to the medical segment, looking at the end-user price, gross margin would be considerably higher. Our sales go through a distributor, and distributors get substantial discounts. As a result, gross margin drops a great deal. In industrial, we more frequently have direct access to sales. Take Lasit, for example, where we have all those distribution companies across Europe. That's why we can capture better margins. The problem with EBIT margins is that we have to reach a certain sales volume, and as you noticed, the start of 2026 wasn't that brilliant from this standpoint. We don't see any structural problem. We see that our customer relationships, the potential deals, and to some extent the backlog as well, are trending in a direction that gives us hope and lets us count on a recovery in the second half of the year.

Valentin Paul-Jahan

analyst
#64

Appreciate it.

Bianca Fersini-Mastelloni

unknown
#65

Apologies. There's another question coming in from Andrea Bonfà at Banca Akros. Please proceed, Andrea.

Andrea Bonfà

analyst
#66

Thanks once more. Andrea, my question is a fairly general one. Given where the technology stands and, say, the competitive landscape in hair removal, is it reasonable to expect that the mix of your product will keep broadening — in the best-performing one, if I can put it that way? Or when it comes to volume, is the balance going to stay as it is?

Andrea Cangioli

executive
#67

As of today, I'd answer in the affirmative. That's the sense we're picking up from the market — the sense telling us we're still asked more often to supply anti-aging or general dermatologic devices rather than hair removal devices, and that ought to keep being the case. After that, we're pursuing new developments aimed at raising the performance of our systems. We're aware that competitors too — not the low-cost Far East competitors, but likewise the segment's main players, namely Candela and Cynosure Lutronic, Lumenis, and Alma — are, let's say, attempting to revive that market segment by bringing new devices to market. We'll raise the performance of our devices, and we might, perhaps, reverse the decline of this segment in some way. As things stand right now, your statement is fair. I don't anticipate our product mix structure within aesthetics shifting over the very next quarters.

Andrea Bonfà

analyst
#68

I appreciate it.

Andrea Cangioli

executive
#69

Naturally, competition exists in every single segment we operate in, and at the moment we're seeing the upside from selling high-margin products within the anti-aging space. As I mentioned, copies of our Onda PRO systems are pouring into the market. That tells you something about where competition is heading — rivals are attempting to go up against us while also steering clear of us so they can capture more market share and push margins even higher. It's hard to predict how the competitive landscape will look six months out — not regarding our mix, but regarding our competitors' mix — and whether we'll manage to hold the same trajectory and the same margin across each and every one of those segments. That's very difficult to forecast, since this is a market where innovation reaches end users quite frequently. We bring it constantly, and that's our strength. Our competitors also do so constantly, and we don't necessarily come out on top every time in that contest. We possess every tool needed to compete effectively. Today we're very successful. We expect to be very successful going forward as well, but it isn't so deterministic.

Bianca Fersini-Mastelloni

unknown
#70

I'd like to bring Valentin back in once more, since I may have cut his mic off too soon. Valentin, do you have another question for us?

Valentin Paul-Jahan

analyst
#71

No, thanks. I appreciate it, but I'm fine.

Bianca Fersini-Mastelloni

unknown
#72

All right. At this point, there are no further questions. Prior to wrapping up the Q&A, I'd like to check one more time whether any additional question remains from investors who are still on the line. Give me a moment — yes, Andrea Bonfà is with us once more.

Andrea Bonfà

analyst
#73

Hi, thanks. Andrea, I was meaning to ask you whether there’s any news on the MonaLisa Touch. Where does that stand right now?

Andrea Cangioli

executive
#74

MonaLisa Touch on its own is doing fine, though the volume has come down. We don't think it makes sense right now to put a very big investment behind getting a return on that exact technology here in the United States, where we enjoyed such big success through 2017. We're looking into other technologies that could be used alongside CO2 laser technology or instead of it, so that vaginal atrophy treatment can be delivered effectively together with the CO2 laser. Demand for this type of treatment is high and it's significant. CO2 isn't as popular as it once was. Over the coming years, I'd say, we may well decide to go to market with a new technology that would be an innovation both for us and for the market. As of today, I can't say what we're considering, and naturally I don't have a date. Perhaps, if you keep putting this question to me, not next quarter but six months to nine months from now, we'd have something new to share about this market segment.

Andrea Bonfà

analyst
#75

Thanks a lot.

Bianca Fersini-Mastelloni

unknown
#76

Andrea, there are no more questions right now. Should anything else come up down the road, feel free to reach out to Enrico Romagnoli, and he will be glad to help. Many thanks for joining today's conference call. We look forward to having you with us again next time. Goodbye, everyone.

Read the full transcript via the API

You're viewing the first half of this call. Get the complete EL.En. S.p.A. transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.

Get the API View API docs →

This call discussed

For developers and AI pipelines

Programmatic access to EL.En. S.p.A. earnings transcripts and 132,000+ others is available through the EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments, full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.

More tools for stock research

OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in EL.En. S.p.A. or any ticker on your watchlist.

StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.